

Resource Summary Report

Generated by [kravitz2](#) on Sep 4, 2026

NEWMEDS

RRID:SCR_003872

Type: Tool

Proper Citation

NEWMEDS (RRID:SCR_003872)

Resource Information

URL: <http://www.newmeds-europe.com/>

Proper Citation: NEWMEDS (RRID:SCR_003872)

Description: Consortium that will develop new models and methods to enable novel treatments for schizophrenia and depression including three important missing tools that will facilitate the translation of scientific findings into benefits for patients. The project will focus on developing new animal models which use brain recording and behavioral tests to identify innovative and effective drugs for schizophrenia. The project will develop standardized paradigms, acquisition and analysis techniques to apply brain imaging, especially fMRI and PET imaging to drug development. It will examine how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it will try and develop new approaches for shorter and more efficient trials of new medication - trials that may require fewer patients and give faster results.

Abbreviations: NEWMEDS

Synonyms: Novel Methods leading to New Medications in Depression and Schizophrenia, NEWMEDS - Novel Methods leading to New Medications in Depression and Schizophrenia

Resource Type: consortium, data or information resource, organization portal, portal

Keywords: drug, biomarker, neuroimaging, drug development, tool development, animal model, fmri, pet, gene, medicine, clinical trial, genetic variation, molecule, model, dna, protein

Funding: Innovative Medicines Initiative 115008; EFPIA

Resource Name: NEWMEDS

Resource ID: SCR_003872

Alternate IDs: nlx_158196

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260903T234635+0000

Ratings and Alerts

No rating or validation information has been found for NEWMEDS.

No alerts have been found for NEWMEDS.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Tripathi A, et al. (2020) Cognition- and circuit-based dysfunction in a mouse model of 22q11.2 microdeletion syndrome: effects of stress. Translational psychiatry, 10(1), 41.

Gamo NJ, et al. (2017) Valley of death: A proposal to build a "translational bridge" for the next generation. Neuroscience research, 115, 1.

Rame M, et al. (2017) Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation. PloS one, 12(5), e0177036.

Alsi?? J, et al. (2015) The role of 5-HT2C receptors in touchscreen visual reversal learning in the rat: a cross-site study. Psychopharmacology, 232(21-22), 4017.

Tansey KE, et al. (2013) Contribution of common genetic variants to antidepressant response. Biological psychiatry, 73(7), 679.

Gastambide F, et al. (2013) Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 23(11), 1414.